Kardi Kennedy,Kathy Vu,Nadia Coakley et al.
Kardi Kennedy et al.
Background: This evidence-based practice guideline was developed to update and address new issues in the handling of hazardous drugs including being compliant with NAPRA (National Association of Pharmacy Regulatory Authorities) and USP 800 ...
Medication errors in cancer therapy: Reports from German hospital pharmacists between 2008 and 2019 [0.03%]
癌症治疗中的药物错误：2008年至2019年德国医院药剂师的报告
Lisa Weber,Claudia Langebrake,Gesine Picksak et al.
Lisa Weber et al.
Objective: Since medication errors can have severe consequences, the development of methods to improve patient safety is becoming increasingly important. The aim of this evaluation was to identify frequent medication erro...
Pharmacokinetic characterization, benefits and barriers of subcutaneous administration of monoclonal antibodies in oncology [0.03%]
肿瘤学中单克隆抗体皮下给药的药代动力学特征、益处和障碍
Ana Homšek,Jelena Spasić,Neda Nikolić et al.
Ana Homšek et al.
Objective: Therapeutic monoclonal antibodies in oncology are slowly becoming the dominant treatment option for many different cancer types. The main route of administration, infusion, requires extensive product preparatio...
Non-Hodgkin's lymphoma developed during imatinib mesylate treatment of chronic myeloid leukemia [0.03%]
慢性髓细胞性白血病患者在甲磺酸伊马替尼治疗期间发生的非霍奇金淋巴瘤
Olfa Kassar,Aicha Ben Kahla,Asma Koubaa et al.
Olfa Kassar et al.
Introduction: Non-Hodgkin lymphoma induced by imatinib, as a tyrosine kinase inhibitor, is a rare complication. Case report: A 54-year-...
Cost-effectiveness of poly-(ADP-ribose) polymerase (PARP)-inhibitors for the maintenance treatment after responding to first- and second-line chemotherapy in advanced ovarian cancer [0.03%]
对晚期卵巢癌患者而言，在一线和二线化疗后使用聚（ADP核糖）聚合酶(PARP)抑制剂进行维持治疗的成本效果分析
Jacopo Giuliani,Beatrice Mantoan,Lucrezia Ferrario et al.
Jacopo Giuliani et al.
The introduction of inhibitors of poly-(ADP-ribose) polymerase (PARP) for the treatment of women with epithelial ovarian cancers (EOC) has radically changed the treatment in maintenance setting after responding to first- and second-line che...
Mercaptopurine induced myelosuppression in a child with a NUDT15 rs116855232 homozygous variant [0.03%]
NUDT15 rs116855232纯合变异儿童中由巯基嘌呤诱发的骨髓抑制
Navya Gupta,Latha Sneha Magatha,Dhaarani Jayaraman et al.
Navya Gupta et al.
Introduction: Mercaptopurine (6-MP) is the backbone of the consolidation and maintenance therapy for paediatric acute lymphoblastic leukaemia (ALL). Nevertheless, it can cause critical myelosuppression. Predicting adverse...
Transition to ePrescribing for systemic anti-cancer therapy - Perceptions of a multidisciplinary haematology/oncology team in a large teaching hospital [0.03%]
向系统性抗癌症治疗的电子处方过渡- 大教学医院中多学科血液学/肿瘤学团队的看法
Hannah O&#x;Connor,Gail Melanophy,Carlos Medina Martin et al.
Hannah O&#x;Connor et al.
Introduction: A National Cancer Information System is planned for phased implementation in Irish cancer centres to enable electronic prescribing (ePrescribing) of systemic anti-cancer therapy. This study aimed to capture ...
Use, response and outcomes of second-line chemotherapy in patients with advanced biliary tract cancers [0.03%]
晚期胆道癌二线化疗的使用、反应及预后分析
Brittney Mathers,Shirin Abadi,Janine M Davies et al.
Brittney Mathers et al.
Introduction: First-line chemotherapy for advanced biliary tract cancers has been established as gemcitabine and cisplatin; however, there is currently no recognized standard second-line chemotherapy. The purpose of this ...
Processes and perceptions of chemotherapy supply chain in Ethiopia: A mixed-method study [0.03%]
埃塞俄比亚化疗供应链的过程与认知：一种混合方法研究
Kurtis J Stocker,Andrew Tiemann,Kelly M Brunk et al.
Kurtis J Stocker et al.
Background: The impact and downstream effects of the chemotherapy supply chain in Ethiopia are not well understood. The purpose of this study was to identify perceived gaps in supply chain and characterize their impact on...
Comparative cost savings of biosimilar and dose rounding utilization in oncology care [0.03%]
肿瘤护理中生物类似药和剂量调整的成本节约比较分析
Verona Abdelmeseh,Britny R Brown,Justin P Huynh et al.
Verona Abdelmeseh et al.
Introduction: The exponential rise in cancer costs has led many centers to utilize dose rounding to the nearest vial size when the difference in dose is ≤10% to decrease costs. The recent approval of several biosimilar p...